Qualigen Therapeutics, Inc. — Director's Dealing 2017

Oct 27, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: RITTER PHARMACEUTICALS INC (RTTR)
CIK: 0001460702
Period of Report: 2017-10-03

Reporting Person: Doyle Noah (Director, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-10-03	Common Stock	P	5000000	—	Acquired	7047804	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-10-03	Warrants (right to buy)	$.44	P	5000000	Acquired	2022-10-03	Common Stock (5000000)	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	322753	Indirect
Common Stock	22727	Direct

Footnotes

F1: Javelin Venture Partners, L.P. ("Javelin") purchased 5,000,000 Class A Units of the Issuer, consisting of 5,000,000 shares of common stock and warrants to purchase 5,000,000 shares of common stock, in the Issuer's October 2017 public offering at the public offering price of $0.40 per Class A Unit. The shares of common stock and warrants that are part of the Class A Units sold to Javelin in the puble offering were immediately separable and were issued separately in the offering.

F2: As the managing director of Javelin, the Reporting Person may be deemed the beneficial owner of the securities sold to Javelin in the public offering. The Reporting Person expressly disclaims beneficial ownership over these securities except to the extent of his pecuniary interest therein.

F3: As the managing director of Javelin Venture Partners I SPV I LLC. the Reporting Person may be deemed the beneficial owner of these shares. The Reporting Person expressly disclaims beneficial ownership over these shares except to the extent of his pecuniary interest therein.